半乳糖凝集素-3对孤立性冠状动脉旁路移植术后长期生存的预测价值
本研究基于北部新英格兰心血管疾病研究组心脏手术登记的前瞻性生物标志物队列(N=1690),检测择期孤立性冠状动脉旁路移植术(CABG)患者术前半乳糖凝集素-3(Gal-3)水平并按四分位数分组,采用Kaplan-Meier生存分析和Cox回归模型(校正STS协作组概率计算器变量)评估Gal-3与6年生存的关系。结果发现最高四分位组Gal-3水平与最低四分位组相比,校正后死亡风险显著增加(HR 2.22;95%CI 1.40-3.54;P=.001),中间四分位组未见生存率下降。
要点
- 术前Gal-3最高四分位组与最低组相比,6年死亡风险显著增加(HR 2.22;95%CI 1.40-3.54;P=.001)。
- 中间四分位组Gal-3水平与最低组相比,生存率无显著下降(HR 1.36;95%CI 0.87-2.12;P=.177)。
- 术前血清生物标志物可用于CABG术后风险分层或预后评估。
核心结论
- 术前Gal-3水平升高与孤立性CABG术后远期死亡风险显著相关。
研究设计与样本
- 前瞻性生物标志物队列研究,纳入2004至2007年北部新英格兰心血管疾病研究组心脏手术登记中接受孤立性CABG的患者,共1690例。
- 术前检测Gal-3水平并按四分位数分组,采用Kaplan-Meier生存分析和Cox回归模型评估6年生存,校正STS协作组概率计算器变量。
主要发现
- 术前Gal-3水平范围为1.72-28.89 ng/mL(均值8.96 ng/mL;中位数8.06 ng/mL;四分位距5.42-11.08 ng/mL)。
- 粗生存率随Gal-3四分位数升高而下降。
- 校正后,最高四分位组Gal-3水平与最低四分位组相比,生存率显著降低(HR 2.22;95%CI 1.40-3.54;P=.001)。
- 中间四分位组与最低四分位组相比,生存率无显著下降(HR 1.36;95%CI 0.87-2.12;P=.177)。
临床怎么用
- 术前Gal-3检测可用于孤立性CABG术后风险分层或术后预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Galectin-3 (Gal-3) is a well-established biomarker of adverse clinical outcomes, but its prognostic value for long-term survival after cardiac surgery is not well understood. Elevated levels of Gal-3 have been found to be remarkably associated with higher risk of death in both acute decompensated and chronic heart failure populations. Its prognostic value for long-term survival after cardiac surgery is not known. METHODS: A sample of patients contributing to the Northern New England Cardiovascular Disease Study Group Cardiac Surgery Registry from 2004 to 2007 were enrolled in a prospective biomarker cohort (N = 1690). Preoperative Gal-3 levels were measured and categorized by quartile. We used Kaplan-Meier survival analysis and Cox regression models, adjusting for variables in The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategy probability calculator to evaluate the association between elevated Gal-3 levels and survival to 6 years. RESULTS: Preoperative Gal-3 levels ranged from 1.72 to 28.89 ng/mL (mean, 8.96 ng/mL; median, 8.06 ng/mL; interquartile range, 5.42-11.08 ng/mL). Crude survival decreased by increasing quartile. After adjustment, serum levels of Gal-3 in the highest quartile of the cohort were associated with significantly decreased survival compared with the lowest quartile (hazard ratio [HR] 2.22; 95% confidence interval [CI], 1.40-3.54; P = .001). No decrease in survival was found for the middle quartiles (HR 1.36; 95% CI, 0.87-2.12; P = .177). CONCLUSIONS: A substantial association was found between elevated preoperative Gal-3 levels and risk of mortality after isolated coronary artery bypass grafting surgery. An assessment of the relationship between preoperative serum biomarkers and long-term survival can be used for risk stratification or estimating postsurgical prognosis.
引用
- Parker DM, Owens SL, Ramkumar N, et al. Galectin-3 as a Predictor of Long-term Survival After Isolated Coronary Artery Bypass Grafting Surgery. Ann Thorac Surg. 2019. PMID: 31336070. doi:10.1016/j.athoracsur.2019.05.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。